Novartis: Lymphoma, Non-Hodgkin trials
The registry lists 19 Lymphoma, Non-Hodgkin studies with Novartis as lead sponsor. 1 are open to participants now and 8 have results posted.
Phase 1 12Phase 2 8Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedNCT03610724Phase 2Results posted
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin LymphomaCompletedNCT03570892Phase 3Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
- Safety and Efficacy of BKM120 in Relapsed and Refractory NHLCompletedNCT01693614Phase 2Results posted
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)CompletedNCT01685008Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT01294579Phase 2Results posted
- Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing TherapyTerminatedNCT01200589Phase 3Results posted
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
- Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHLTerminatedNCT04240704Phase 1
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
- Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular LymphomaCompletedNCT01275209Phase 1
- Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior TherapiesCompletedNCT00670592Phase 1/2
- A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00622258Phase 1
- A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsCompletedNCT00503451Phase 1
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1